VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q3 2025
Holdings as of Sep 30, 2025, filed Nov 14, 2025. Long positions only; changes compare share counts with Q2 2025.
- Positions
- 33
- +2 vs. Q2 2025
- Portfolio value
- $1.78B
- +$442.3M (+33.1%) vs. Q2 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CASIFCASI Pharmaceuticals, Inc. | ORD SHS | 987,259 | $1.64M | 0.1% | 00.0% | Unchanged | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 437,708 | $3.33M | 0.2% | +339,144+344.1% | Added | History |
| ARTVArtiva Biotherapeutics, Inc. | COM | 1,609,569 | $4.62M | 0.3% | 00.0% | Unchanged | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.95M | 0.4% | 00.0% | Unchanged | History |
| SRZNSurrozen, Inc. | COM NEW | 632,931 | $8.16M | 0.5% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 1,379,965 | $8.18M | 0.5% | 00.0% | Unchanged | History |
| SEPNSepterna, Inc. | COM | 610,808 | $11.5M | 0.6% | +70,355+13.0% | Added | History |
| CBIOCrescent Biopharma, Inc. | COM | 1,387,864 | $16.5M | 0.9% | 00.0% | Unchanged | History |
| PHVSPharvaris N.V. | COM | 674,599 | $16.8M | 0.9% | −1,373,021−67.1% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,457,348 | $17.9M | 1.0% | 00.0% | Unchanged | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 4,631,216 | $20.1M | 1.1% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 1,169,298 | $22.0M | 1.2% | −1,126,021−49.1% | Reduced | History |
| VORVor Biopharma Inc. | COM NEW | 499,966 | $24.4M | 1.4% | +499,966 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $27.5M | 1.5% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM NEW | 3,220,364 | $27.8M | 1.6% | 00.0% | Unchanged | History |
| MAZEMaze Therapeutics, Inc. | COM | 1,230,769 | $31.9M | 1.8% | +1,230,769 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 5,046,414 | $34.5M | 1.9% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 960,803 | $37.8M | 2.1% | −39,197−3.9% | Reduced | History |
| ERASErasca, Inc. | COM | 17,857,083 | $38.9M | 2.2% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,685,448 | $45.0M | 2.5% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,681,043 | $45.3M | 2.5% | +3,796,780+42.7% | Added | History |
| ABVXAbivax S.A. | SPONSORED ADS | 576,729 | $49.0M | 2.8% | −769,051−57.1% | Reduced | History |
| CTMXCytomX Therapeutics, Inc. | COM | 15,561,500 | $49.6M | 2.8% | +1,591,618+11.4% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 4,000,000 | $57.4M | 3.2% | −755,411−15.9% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 3,226,331 | $66.0M | 3.7% | −800,000−19.9% | Reduced | History |
| ORICOric Pharmaceuticals, Inc. | COM | 6,596,885 | $79.2M | 4.5% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 4,148,428 | $79.8M | 4.5% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 6,728,985 | $82.0M | 4.6% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,882,709 | $83.8M | 4.7% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 946,788 | $90.7M | 5.1% | +307,700+48.1% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 13,161,462 | $153.9M | 8.7% | +399,000+3.1% | Added | History |
| MTSRMetsera, Inc. | COM | 3,750,662 | $196.3M | 11.0% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 8,493,321 | $337.4M | 19.0% | 00.0% | Unchanged | History |